The Big Picture
The material here comes from three Huberman Lab conversations, two with Matthew Johnson, whose group runs psilocybin sessions at Hopkins, and one with Nolan Williams, whose work spans psychedelics and brain stimulation. Both treat psychedelics as serious candidates for treating depression, addiction and trauma, and both are careful about what the evidence does and does not show [1][2][3]. Williams points to evidence for MDMA in PTSD and psilocybin in depression, and also discusses ibogaine, 5-MeO-DMT and ayahuasca [2]. Johnson's interest is in what he calls big effects: durable improvements from one to three high-dose sessions [3].
What stands out is how much of the treatment, as Johnson describes it, is not the drug. It is the screening, the hours of preparation and the relationship with guides that surround the session [1]. The sharpest open question across the conversations is whether the altered experience itself does the healing, or whether the chemistry would work without it [1][2].
Where the Experts Agree
- Depression is a major target. Williams calls depression the most disabling condition worldwide and a risk factor for heart disease [2]. Johnson notes that depression is a serious problem in adolescents [3].
- These are treatments delivered under careful conditions, not casual use. At Hopkins, participants first go through a couple of days of screening, with structured psychiatric interviews to exclude psychotic disorders and bipolar disorder, plus cardiovascular checks [1]. Then come roughly four to eight hours of preparation, building rapport with the guides and learning what could happen [1].
- The experience is unpredictable. Johnson calls psychedelics "all arounders," in contrast to uppers and downers: you could have the most beautiful or the most terrifying experience of your life, so the aim is that nothing comes as a surprise [1]. Williams highlights the role of "letting go" [2].
- Ketamine acts fast. Johnson says ketamine's antidepressant effect kicks in immediately but lasts about a week, while his group sees effects from psilocybin a year or more later [1]. Williams also covers ketamine as an antidepressant [2].
- Psychiatry is changing its model. Williams describes a move from the idea of a chemical imbalance to fixable circuits, which he calls "psychiatry 3.0" [2].
Where They Differ
Does the "trip" matter? This is the main tension. Johnson points out that ketamine is not given as psychedelic therapy: patients are essentially told to ignore the altered experience as a side effect [1]. He cites older work in Russia by Krupitsky that used higher ketamine doses framed as psychedelic therapy, with preparation and discussion, and reported very high success rates for heroin and alcohol addiction, and he wonders whether ketamine clinics would get more out of the drug if they treated it the same way [1]. Williams discusses a study showing that ketamine's antidepressant effect depends on opioid receptors, not the "trip" [2]. So for ketamine at least, one researcher wonders whether the experience and its framing are being wasted, while the other points to evidence that the benefit runs through receptor chemistry [1][2]. For classic psychedelics, Williams's mention of "letting go" suggests the experience still counts [2].
Drugs or devices? Johnson's focus stays on psychedelic sessions [1][3]. Williams places psychedelics alongside neurostimulation, including SAINT/SNT, an accelerated, individually targeted TMS protocol that he says can bring remission in days [2].
A few big sessions versus frequent dosing. Johnson is skeptical of the claims made for regular, repeated dosing. The studies so far, he says, have shown no improved creativity, cognition or sustained mood, though none has yet modeled the intermittent dosing schedules promoted by advocates like Paul Stamets [3]. His bet, based on anecdotes, is that any real effect is most likely antidepressant, like a better SSRI [3]. Huberman notes, citing his Stanford colleague Alia Crum's research on belief effects, that placebo is part of all medicine [3].
Safety over time. Johnson raises a caution specific to frequent use: most common psychedelics, including MDMA, also stimulate the serotonin 2B receptor, which has been linked to heart valve problems and was why fen-phen was pulled from the market [3]. He says that is not a concern for a few therapeutic sessions, but taking something twice a week for years is a different question [3].
Practical Takeaways
- Understand that the research model is one to three high-dose sessions with screening and preparation, not regular unsupervised use [1][3].
- Know who is screened out of the Hopkins studies: people with psychotic disorders or bipolar disorder, and those who fail cardiovascular checks [1].
- Expect preparation to matter; the goal is that nothing in the session comes as a surprise [1].
- Treat claims for regular small-dose routines with caution: Johnson says the studies so far show no benefit for creativity, cognition or sustained mood [3].
- Weigh the heart valve question before considering any frequent, long-term dosing [3].
- If considering ketamine, know that its antidepressant effect is fast but, per Johnson, lasts about a week [1].
- Remember that there is no formal research on psychedelic therapy in people under 18, though Johnson expects it [3].
- Ask about non-drug options too; Williams describes a targeted TMS protocol for severe depression [2].
